What topics does this cannabis study cover?

This study covers research on: Cancer.

Cannabinoids and melatonin could cut cancer drug toxicity by 75%

Q: What did this research study find?

This groundbreaking research demonstrates that combining **cannabinoids with melatonin can dramatically enhance cisplatin's effectiveness** against bone cancers (*osteosarcoma* and *chondrosarcoma*) while reducing toxic side effects. Scientists tested *CBD* and *THC* alongside melatonin in cancer ce

Q: Where was this research published?

Published in Naunyn-Schmiedeberg's archives of pharmacology on June 27, 2026.

A selective low-dose cisplatin strategy enabled by melatonin and cannabinoids for targeting osteosarcoma and chondrosarcoma.

Naunyn-Schmiedeberg's archives of pharmacology • June 27, 2026 • Moderately Relevant

🤖

AI Summary

This groundbreaking research demonstrates that combining cannabinoids with melatonin can dramatically enhance cisplatin's effectiveness against bone cancers (osteosarcoma and chondrosarcoma) while reducing toxic side effects. Scientists tested CBD and THC alongside melatonin in cancer cells, finding that the three-compound combination—particularly THC + cisplatin + melatonin—worked synergistically to kill cancer cells. Most remarkably, this triple combination enabled reducing cisplatin doses by up to 4.38-fold, which is significant given that cisplatin's severe toxicity is a major limitation in cancer therapy today.

The mechanism behind this success involves multiple cancer-fighting pathways working together. The combination treatments triggered apoptosis (programmed cancer cell death) through multiple routes, damaged cancer cell DNA, disrupted mitochondrial function, and suppressed cancer cell migration and invasion. Importantly, normal cells remained largely unharmed, suggesting the treatments selectively target cancer while sparing healthy tissue—a critical advantage over conventional chemotherapy.

These findings open promising new therapeutic avenues for patients with bone sarcomas, a particularly challenging group. By enabling such significant dose reduction while maintaining or improving anti-cancer effectiveness, this multi-target combinatorial strategy could substantially reduce patients' exposure to cisplatin's notorious side effects including kidney damage, hearing loss, and severe nausea. While these results come from laboratory cell studies and will require clinical validation, they represent compelling evidence that cannabinoids and melatonin merit serious investigation as chemotherapy adjuvants in cancer treatment protocols.

📄 Original Abstract

Therapeutic management of osteosarcoma and chondrosarcoma is limited by cisplatin (CP)-associated systemic toxicity and acquired chemoresistance. Strategies enabling effective dose reduction while maintaining antitumor activity are urgently required. This study investigated whether melatonin (MEL) and cannabinoids (CBD, THC) enhance CP efficacy through synergistic, multi-target mechanisms in osteosarcoma (MG63, Saos2) and chondrosarcoma (SW1353) cells, with normal fibroblast (FL) and osteoblast (HC) cells as controls. Cytotoxicity and antiproliferative effects were evaluated using MTT and LDH assays. Drug interactions were quantified via combination index (CI) and dose-reduction index (DRI) analyses. Apoptotic mechanisms were assessed by Casp3, Casp8, Casp9, and Bax gene expression, DNA fragmentation, DAPI nuclear staining, and Rhodamine-123-based mitochondrial membrane potential analysis. Anti-migratory and anti-invasive effects were examined using wound-healing and invasion assays. Molecular docking was performed to predict interactions with COX-2, MMPs, ADAMTS-5, and MAPK pathway proteins. Combination regimens, particularly THC + CP + MEL, and CP + MEL, demonstrated strong synergism (CI < 1) in SW1353 and Saos2 cells, enabling up to a 2.77 - 4.38-fold reduction in CP dose. Synergistic treatments significantly upregulated apoptotic markers and induced selective DNA fragmentation, chromatin condensation, and mitochondrial depolarization in cancer cells, while normal cells showed minimal alterations. Cannabinoids markedly suppressed migration and invasion, effects further enhanced in combination treatments. Docking analyses supported high-affinity multi-target interactions consistent with the observed biological responses. Collectively, melatonin enhances cannabinoid-mediated chemosensitization to cisplatin through selective, pro-apoptotic and anti-invasive mechanisms, supporting a low-dose, multi-target combinatorial strategy for bone sarcoma therapy.

Paper Type

📄 Research

Publication

Journal: Naunyn-Schmiedeberg's archives of pharmacology
Published: June 27, 2026
PMID: 42362763
DOI: 10.1007/s00210-026-05551-y

Authors (5)

Davut Aydın Department of Medical Biology, Institute of Health Sciences, Erciyes University, 38030, Melikgazi, Kayseri, Turkey.
Aylin Korkmaz Pınarbaşı Department of Medical Biology, Faculty of Medicine, Yozgat Bozok University, 66200, Yozgat, Turkey.
Kübra Aslan Department of Medical Biology, Faculty of Medicine, Erciyes University, 38030, Melikgazi, Kayseri, Turkey.
Ali Aydın Department of Medical Biology, Faculty of Medicine, Yozgat Bozok University, 66200, Yozgat, Turkey.
Halit Canatan Department of Medical Biology, Institute of Health Sciences, Erciyes University, 38030, Melikgazi, Kayseri, Turkey. halitcanatan@yahoo.com.